ALNYLAM PHARMACEUTICALS, INC. - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K, dated February 15, 2005, reports the financial results for Alnylam Pharmaceuticals, Inc. for the year and quarter ended December 31, 2004. The company is incorporated in Delaware and headquartered in Cambridge, MA.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These details are contained within the press release furnished as Exhibit 99.1, which is referenced but not included in the body of this report.
Material Changes
The filing does not explicitly detail material changes versus the prior comparable period within the main text. Investors must refer to the attached press release (Exhibit 99.1) for comparative analysis.
Guidance, Outlook, and Risks
Management commentary, future guidance, specific risks, contingencies, and unusual items are not detailed in this summary document. The report explicitly states that the information in Exhibit 99.1 is furnished and not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated February 15, 2005) for actual financial figures.
- Verify the specific revenue and net loss figures for the year ended December 31, 2004.
- Confirm cash position and burn rate details from the full press release.
- Check for any updates on clinical trial progress or partnership announcements mentioned in the press release.